Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 20.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,386 shares of the medical equipment provider’s stock after selling 3,181 shares during the period. ProShare Advisors LLC’s holdings in Lantheus were worth $994,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of LNTH. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after buying an additional 100 shares during the period. Moody National Bank Trust Division lifted its stake in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after acquiring an additional 162 shares during the last quarter. NBC Securities Inc. lifted its stake in Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after acquiring an additional 191 shares during the last quarter. GAMMA Investing LLC grew its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares in the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Lantheus by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider’s stock valued at $5,353,000 after purchasing an additional 226 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of analyst reports. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Leerink Partners raised their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Truist Financial lowered their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Finally, JMP Securities lowered their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Stock Up 2.8 %

Shares of NASDAQ:LNTH opened at $107.36 on Friday. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The stock has a market cap of $7.44 billion, a P/E ratio of 16.39 and a beta of 0.50. The firm has a fifty day moving average price of $104.45 and a 200 day moving average price of $85.86.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. Lantheus’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the company posted $1.40 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Insider Activity

In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock valued at $3,922,001. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.